A Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

Clinical Trial ID NCT02477826

Rank	Title	Journal	Year	PubWeight™‹?›
1	Checkpoint inhibitors in lung cancer: latest developments and clinical potential.	Ther Adv Med Oncol	2016	0.96
2	Advances in immunotherapy for treatment of lung cancer.	Cancer Biol Med	2015	0.95
3	Immunotherapy for lung cancer: advances and prospects.	Am J Clin Exp Immunol	2016	0.89
4	Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.	Drugs Context	2015	0.84
5	New targeted treatments for non-small-cell lung cancer - role of nivolumab.	Biologics	2016	0.79
6	Recent Advances in Immunotherapy in Metastatic NSCLC.	Front Oncol	2016	0.79
7	Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.	Transl Lung Cancer Res	2015	0.78
8	Chemotherapy remains an essential element of personalized care for persons with lung cancers.	Ann Oncol	2016	0.77
9	Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets.	Nat Rev Clin Oncol	2015	0.76
10	Major milestones in translational oncology.	BMC Med	2016	0.75
11	Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.	Ann Oncol	2016	0.75
12	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.	Onco Targets Ther	2016	0.75
13	Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?	Transl Lung Cancer Res	2016	0.75
14	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.	N Engl J Med	2019	0.75